Fury MG - Search Results

1

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM. Smyth LM, et al. Among authors: fury mg. Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9. Invest New Drugs. 2017. PMID: 28281183 Free PMC article. Clinical Trial.

2

A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.

Fury MG, Krug LM, Azzoli CG, Sharma S, Kemeny N, Wu N, Kris MG, Rizvi NA. Fury MG, et al. Cancer Chemother Pharmacol. 2006 May;57(5):671-7. doi: 10.1007/s00280-005-0080-x. Epub 2005 Aug 31. Cancer Chemother Pharmacol. 2006. PMID: 16136310 Clinical Trial.

3

A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, Pfister DG, Rizvi NA. Fury MG, et al. Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75. doi: 10.1007/s00280-006-0286-6. Epub 2006 Aug 1. Cancer Chemother Pharmacol. 2007. PMID: 16896930 Clinical Trial.

4

A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers.

Fury MG, Zahalsky A, Wong R, Venkatraman E, Lis E, Hann L, Aliff T, Gerald W, Fleisher M, Pfister DG. Fury MG, et al. Invest New Drugs. 2007 Apr;25(2):165-72. doi: 10.1007/s10637-006-9011-x. Epub 2006 Sep 16. Invest New Drugs. 2007. PMID: 16983506 Clinical Trial.

5

A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors.

Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG. Fury MG, et al. Cancer Immunol Immunother. 2008 Feb;57(2):155-63. doi: 10.1007/s00262-007-0357-5. Epub 2007 Jun 30. Cancer Immunol Immunother. 2008. PMID: 17602224 Free PMC article. Clinical Trial.

6

A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.

Hensley ML, Larkin J, Fury M, Gerst S, Tai DF, Sabbatini P, Konner J, Orlando M, Goss TL, Aghajanian CA. Hensley ML, et al. Clin Cancer Res. 2008 Oct 1;14(19):6310-6. doi: 10.1158/1078-0432.CCR-08-0338. Clin Cancer Res. 2008. PMID: 18829514 Clinical Trial.

7

A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.

Fury MG, Haque S, Stambuk H, Shen R, Carlson D, Pfister D. Fury MG, et al. Cancer. 2011 Feb 15;117(4):795-801. doi: 10.1002/cncr.25464. Epub 2010 Oct 4. Cancer. 2011. PMID: 20922785 Free article. Clinical Trial.

8

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.

Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Laurie SA, et al. Among authors: fury mg. Lancet Oncol. 2011 Aug;12(8):815-24. doi: 10.1016/S1470-2045(10)70245-X. Epub 2010 Dec 10. Lancet Oncol. 2011. PMID: 21147032 Review.

9

Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes.

Lok BH, Setton J, Caria N, Romanyshyn J, Wolden SL, Zelefsky MJ, Park J, Rowan N, Sherman EJ, Fury MG, Ho A, Pfister DG, Wong RJ, Shah JP, Kraus DH, Zhang Z, Schupak KD, Gelblum DY, Rao SD, Lee NY. Lok BH, et al. Among authors: fury mg. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1851-7. doi: 10.1016/j.ijrobp.2011.03.029. Epub 2011 Jun 2. Int J Radiat Oncol Biol Phys. 2012. PMID: 21640497 Free PMC article.

10

A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.

Fury MG, Sherman E, Haque S, Korte S, Lisa D, Shen R, Wu N, Pfister D. Fury MG, et al. Cancer Chemother Pharmacol. 2012 Mar;69(3):591-8. doi: 10.1007/s00280-011-1734-5. Epub 2011 Sep 13. Cancer Chemother Pharmacol. 2012. PMID: 21913034 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters